Analysts See $-0.13 EPS for Argos Therapeutics Inc (ARGS)

July 31, 2017 - By Louis Casey

 Analysts See $ 0.13 EPS for Argos Therapeutics Inc (ARGS)
Investors sentiment increased to 2.7 in 2016 Q4. Its up 0.14, from 2.56 in 2016Q3. It improved, as 2 investors sold Argos Therapeutics Inc shares while 8 reduced holdings. 8 funds opened positions while 19 raised stakes. 7.25 million shares or 21.41% more from 5.97 million shares in 2016Q3 were reported.
California State Teachers Retirement owns 29,661 shares. Wasatch Advsrs stated it has 0.24% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS). Vanguard Group Inc Inc has invested 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS). 177,494 are held by State Street. Northern Tru Corporation reported 146,311 shares. D E Shaw Co holds 0% or 39,900 shares in its portfolio. Nationwide Fund stated it has 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS). Wells Fargo & Mn owns 11,132 shares. Bancshares Of America De owns 3,101 shares or 0% of their US portfolio. Morgan Stanley has 51,285 shares. Blackrock Invest Management Ltd Liability Company accumulated 66,859 shares. 9,252 were reported by Deutsche Savings Bank Ag. Blackrock Fund holds 0% or 455,673 shares in its portfolio. Creative Planning reported 6,028 shares. Schwab Charles Invest Mgmt reported 0% stake.

Investors wait Argos Therapeutics Inc (NASDAQ:ARGS) to report on August, 9. its quarterly earnings Wall Street analysts expect $-0.13 earnings per share, up $0.35 or 72.92 % from last year’s $-0.48 same quarter earnings. Argos Therapeutics Inc’s Wall Street analysts see -77.59 % EPS growth, taking into account the $-0.58 EPS reproted in the previous quarter, About 3.12 million shares traded or 32.77% up from the average. Argos Therapeutics Inc (NASDAQ:ARGS) has declined 92.57% since August 1, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Argos Therapeutics had 5 analyst reports since November 16, 2015 according to SRatingsIntel. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) earned “Buy” rating by Needham on Tuesday, November 17. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. FBR Capital maintained the shares of ARGS in report on Thursday, August 11 with “Outperform” rating. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) has “Buy” rating given on Tuesday, April 19 by Roth Capital. On Monday, November 16 the stock rating was maintained by FBR Capital with “Outperform”.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $10.38 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

More recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Bizjournals.com which released: “Argos Therapeutics faces threat of delisting” on May 05, 2017. Also Seekingalpha.com published the news titled: “Argos Therapeutics: What’s In Store After ADAPT’s Failure?” on February 27, 2017. Bizjournals.com‘s news article titled: “Durham’s Argos Therapeutics may file for bankruptcy” with publication date: March 17, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.